Epitel Announces Appointment of Wearables Industry Leader Ken Nelson to Board of Directors

Rhea-AI Summary

Epitel, a pioneer in AI-powered brain health solutions, has announced the appointment of Ken Nelson to its Board of Directors. Nelson, an expert in digital health and remote patient monitoring, brings over 20 years of experience to Epitel. He has held key positions in leading companies such as BioTelemetry, iRhythm, and Bardy Diagnostics, with notable achievements including BioTelemetry's $2.8 billion acquisition by Philips and Bardy Diagnostics' $450 million acquisition by HillRom/Baxter. As Epitel strives to revolutionize brain monitoring with AI and wearable EEG technology, Nelson's strategic insight is expected to drive the company's growth and commercial success. He currently holds influential positions in several MedTech startups and advisory boards.

Positive

• Appointment of Ken Nelson, a leading figure in digital health and remote patient monitoring, to the Board of Directors.
• Nelson's background includes leadership roles that drove successful IPOs and acquisitions, such as BioTelemetry's $2.8 billion acquisition by Philips.
• Epitel's focus on FDA-cleared AI-powered brain health solutions and wearable EEG technology.
• Nelson's strategic vision aligns with transforming the standard of care in brain health monitoring.

Negative

• None.

Innovative Leader in AI-Powered Brain Health Solutions Strengthens Board with Accomplished Remote Patient Monitoring Executive

SALT LAKE CITY--(BUSINESS WIRE)-- Epitel, a leader in AI technologies for patient-focused brain health solutions, announced today the addition of wearables industry pioneer Ken Nelson to its Board of Directors. With his extensive experience in digital health, medical devices, and remote patient monitoring, Nelson will play a crucial role in guiding Epitel's growth as the company continues to transform the landscape of brain monitoring through AI/ML and its wearable EEG technology.

Ken Nelson brings a wealth of knowledge with over 20 years of experience and broad expertise in shaping teams and driving commercial efforts for disruptive technologies in the wearables and remote patient monitoring industries. His extensive commercial leadership experience in digital health and cardiac remote patient monitoring includes pivotal roles in building infrastructures for top market players. His notable achievements include serving as Global VP of Sales at BioTelemetry, VP of Sales & Marketing at iRhythm, and Chief Commercial Officer at Bardy Diagnostics. He most recently held the position of Head of Digital Health, Diagnostics, and Monitoring at Biotronik. His career highlights include leading commercial efforts that contributed to successful IPOs and acquisitions, including BioTelemetry's $2.8 billion acquisition by Philips and Bardy Diagnostics' $450 million acquisition by HillRom/Baxter.

“Ken Nelson brings a wealth of experience and a proven track record in the MedTech and digital health sectors,” said Mark Lehmkuhle, CEO of Epitel. “His strategic insights and leadership will be invaluable as we continue to advance our AI-powered brain health solutions and expand our impact on patient care. We are thrilled to welcome Ken to our Board of Directors.”

Nelson currently serves as a partner in the Medtech Advantage Fund, which has an exclusive partnership with Medtech Innovator, the largest MedTech and Digital Health startup accelerator globally. In addition, he serves as Chairman of the Board for CardiaCare and is an active board member for HeartBeam (NASDAQ: BEAT), Happitech, and several other disruptive cardiac Digital Health and MedTech startups. He is also involved with advisory boards and planning committees for SmartCardia, HeartX, HRX (Digital Health Summit of Heart Rhythm Society), and the American Heart Association's Health Tech Innovation Business Advisory Board and Heart & Brain Accelerator.

Commenting on Epitel’s exciting future, Ken Nelson noted that “With the FDA-cleared innovation Epitel is bringing to market, we will fundamentally change the standard of care in brain health monitoring, starting with a focus on seizures and monitoring of Epilepsy patients and then evolving into other areas of EEG and brain health monitoring. My knowledge of how we were able to turn the cardiac digital health and remote patient monitoring of ECGs into a multi-billion industry is a great example of a roadmap for Epitel to follow and lead the charge in the EEG monitoring space.”

Nelson joins a strong advisory group that includes CEO Mark Lehmkuhle, Vikram Chaudhery of Genoa Ventures, and Josh Phillips of Catalyst Health Ventures.

About Epitel

Epitel is a digital health company modernizing brain health solutions to improve seizure monitoring and detection. By leveraging a proprietary cloud-based wearable sensor system and other innovative AI technologies, Epitel is empowering better treatment decisions by making EEG readily deployable and accessible. Visit www.epitel.com to learn more.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240625928257/en/

Media Contact:

Maya Villanueva

+1 (802) 829-0192

maya@vuturo.com

Source: Epitel Inc.

FAQ

Who is the new board member appointed by Epitel?

Ken Nelson, an expert in digital health and remote patient monitoring, has been appointed to Epitel's Board of Directors.

What experience does Ken Nelson bring to Epitel?

Ken Nelson has over 20 years of experience in digital health and remote patient monitoring, with leadership roles at BioTelemetry, iRhythm, and Bardy Diagnostics.

How might Ken Nelson's appointment impact Epitel's stock symbol BEAT?

Ken Nelson's strategic insight and extensive experience in the digital health sector are expected to positively influence Epitel's growth and potentially boost investor confidence in BEAT.

What notable achievements does Ken Nelson have?

Ken Nelson led commercial efforts that resulted in BioTelemetry's $2.8 billion acquisition by Philips and Bardy Diagnostics' $450 million acquisition by HillRom/Baxter.

What is Epitel's focus under Ken Nelson's guidance?

Under Ken Nelson's guidance, Epitel aims to advance AI-powered brain health solutions and revolutionize brain monitoring with wearable EEG technology.